

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 7

April 14th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- ASCO statement on investigational drugs and “right to try”
- AMA's MACRA/QPP webinar
- Meaningful use exceptions/deadlines
- ANCO's *Hematologic Malignancies Updates*
- ANCO Event at ASCO's *Best of ASCO*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on April 28th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

ASCO strongly supports increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed Federal "right to try" (RTT) legislation as well as enacted State RTT laws.

Read ASCO's full position statement on access to investigational drugs at www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/documents/2017-Access-to-Investigational-Drugs-Position-Statement.pdf?et_cid=39110097&et_rid=1760459169&linkid=full+statement.

The *United States* cancer care delivery system is undergoing profound changes to better meet the needs of people with cancer, but persistent hurdles threaten to slow progress, according to ASCO's fourth annual *State of Cancer Care in America* report. The report is published in the *Journal of Oncology Practice* and was presented at a briefing on *Capitol Hill*. A summary of the report is available at www.asco.org/state-of-cancer-care.

The Medicare Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA) began on January 1st. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. For more information and access to ASCO's QPP tools, educational materials, and resources, go to www.asco.org/advocacy-policy/asco-in-action/macra-implementation-has-begun-will-you-avoid-4-percent-reimbursement. Join the *American Medical Association* (AMA) on April 20th for a free webinar entitled *MACRA/QPP: Medicare Access and CHIP Authorization Act/Quality Payment Program* at 4PM PDT. Register for this webinar at cc.readytalk.com/registration/#/?meeting=22agkgluwqh&c

campaign=3yru6vltfxfh. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information.

CMS has announced that it is now accepting hardship exceptions from the meaningful use requirements of the EHR incentive payment program for the 2016 reporting year. Physicians who can show that demonstrating meaningful use would result in a significant hardship can apply for a one-year exception and avoid a negative payment adjustment in 2018. The deadline is July 1st. Go to www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/PaymentAdj_Hardship.html for more information and applications.

The California *Department of Health Care Services* (DHCS) has announced that it will extend the deadline for Medi-Cal meaningful use reporting for the 2016 program year to May 2nd. After that date, DHCS will only accept 2017 attestations.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The April 2017 edition includes:

- Health Net Federal Services begins TRICARE contracting initiative
- UnitedHealthcare requiring stricter notification requirements for out-of-network ASC referral

- Health Net sends SB137 notice to some docs in error
- CMS to remove SSNs from all Medicare cards by April 2019
- CMA updates MACRA preparation checklist
- Ask the expert: Making a business case to join a payer network
- The Coding Corner: Incident-to billing for Medicare patients.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor (MAC)*. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—MIPS Annual Call for Measures and Activities through June 30; Provider Compliance; Billing for Stem Cell Transplants; Clinical Laboratory Data Reporting: Enforcement Discretion; Open Payments Program Year 2016 Review and Dispute Period Ends May 15; MIPS Group Web Interface and CAHPS Reporting: Registration Period Open through June 30; April Quarterly Provider Update Available
- Claims, Pricers, and Codes*—April 2017 OPPS Pricer File
- Events*—Hospice Quality Reporting Program: Public Reporting Webinar-April 27
- Publications*—NPI: What You Need to Know Booklet-New; SNF Consolidated Billing Web-Based Training Course-Revised; Remittance Advice Resources and FAQs Fact Sheet-Revised; Reading a Professional Remittance Advice Booklet-Revised; Medicare Enrollment for Physicians and Other Part B Suppliers Booklet-Reminder; Medicare Enrollment for Institutional Providers Booklet-Reminder; Safeguard Your Identify and Privacy Using PECOS Booklet-Reminder; SNF Value-Based Purchasing Call: Audio Recording and Transcript-New; PECOS for Physicians and Non-

Physician Practitioners Booklet-Reminder; Quality Payment Program in 2017: Pick Your Pace Web-Based Training Course-New

- Laboratory NCD Edit Software-Changes for July 2017 CR10036
- MolDX: APC and MUTYH Gene Testing Panel LCD-Effective May 15, 2017
- MolDX-CDD: Oncotype DX Breast Cancer for DCIS (Genomic Health) LCD-R1
- MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease LCD-R4
- MolDX: MMACHC, VEGFR2, FDA Approved ALK Companion Diagnostic Tests Billing and Coding Guidelines
- Open Public Meeting Announcement-June 1, 2017
- Bladder/Urothelial Tumor Markers Final LCD-Effective May 16, 2017
- Documentation Guidelines for Amended Medical Records
- MolDX-CDD: ProMark Risk Score Final LCD-Effective June 1, 2017
- Evaluate Our Services
- Redetermination Requests Require Signatures
- New Waived Tests-Revised CR9956
- Contractor Status Codes (C-Status) Updates

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming Noridian/JEMAC meetings/workshops include:

- Preventive Services (April 26)
- Noridian Medicare Portal Registration and Functionality (May 2, May 17)
- Modifier 59 (May 4, May 10)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

According to *Noridian/JEMAC*, their coverage edits for HCPCS code G0498 currently only covers the code when used with trabectedin (J9999) and this is an error. They are currently updating their coverage edits to include additional drugs (J codes) that could be infused via pump over an extended period-of-time. A new coverage article is being prepared and will be published by *Noridian/JEMAC* very soon. It will include several additional covered drugs, including J9000 (doxorubicin), J9181 (etoposide), J9190 (flourouracil), and J9371 (vincristine). Additional drugs will be added as necessary. A mass adjustment has been ordered. Until then, practices may appeal denials to be overturned.

Beginning April 1st, *Noridian/JEMAC's* Medicare portal requires multi-factor authorization process for users. This adds a second layer of security to your *Noridian/JEMAC* account. Go to med.noridianmedicare.com/web/jeb/article-detail/-/view/10546/multi-factor-authentication-required-on-noridian-medicare-portal-beginning-april-1-2017 for more information.

Anthem Blue Cross has implemented important changes to its national drug list (formulary) effective April 1st. Review these changes at file.anthem.com/s3-website-us-east-1.amazonaws.com/64774CAEENABC.pdf.

Anthem Blue Cross has announced that effective May 15th, *Myriad Genetic Laboratories* will no longer be an in-network laboratory provider. A complete list of in-network participating laboratories may be obtained online at www.anthem.com/ca > Provider > Find a Doctor.

The *Anthem Network Update* (April 2017) is now available online at www11.anthem.com/ca/provider/f5/s3/t3/pw_g304937.pdf and features articles entitled *Clinically equivalent agents*; *Medical policy update*; *Clinical guideline informational notices*; *Anthem Blue Cross will be expanding the Specialty Pharmacy prior authorization list*.

UnitedHealthcare's Network Bulletin (April 2017) is now available online at www.unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles entitled *Enhanced claimsLink App Replacing Other Online Options*; *Notification of Addendum to Administrative Guide*; *New Prior Authorization Requirement for Levoleucovorin*; *Changes in Advance*

Notification and Prior Authorization Requirements

UnitedHealthcare's commercial reimbursement policies will begin requiring biosimilar biological products to include a modifier that identifies the manufacturer of the specific product for dates of service on or after June 1st. Specifically, the modifier for Q5101 (filgrastim) Zarxio will be ZA (Novartis/Sandoz) and the modifier for Q5102 (infliximab) Inflectra will be ZA (Pfizer/Hospira).

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The first *Update* will take place on May 6th at the *Sacramento Hyatt Regency* with Mehrdad Abedi, M.D., *University of California, Davis*, Sandy Wong, M.D., *University of California, San Francisco*, and Julian Davis, M.D., *University of California, Davis*. The latest research on novel treatment modalities for hematologic malignancies, myeloma, and amyloidosis, along with case studies for these diagnoses will be presented. These updates are supported by *Janssen Biotech*, *Merck*, *Pfizer Oncology*, and *Pharmacyclics*. Download the meeting announcement and registration form at www.anco-online.org/2Q2017HemeMaligUpdate.pdf.

SAVE THE DATE

ANCO Event at ASCO's Best of ASCO 2017

ANCO's *ASCO Highlights* will not take place in 2017 in lieu of our encouragement of members to attend ASCO's *Best of ASCO* in San Francisco (west-boa.asco.org; June 16-17th). However, ANCO will host an event on June 15th entitled *The State of Cancer Care* with Margaret Tempero, M.D., and Wes Kidder, M.D., *University of California, San Francisco*, at the *San Francisco Marriott Marquis*. Watch for a meeting announcement in late April.

Additional Education MeetingsApril 20th-22nd*Cancer Metastasis through the Lymphovascular System: Biology & Treatment—7th International Symposium*

Sentinel Node Oncology Foundation

San Francisco

www.cancermetastasis.orgApril 21st*New Perspectives in the Treatment of Advanced Skin Cancer: Basal Cell and Squamous Cell Cancers (Part I of Living with Advanced Skin Cancer)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsApril 27-28th*The 2017 Community Oncology Conference: Fueling the Cancer Moonshot*

Community Oncology Alliance

Washington, D.C.

<http://www.coaconference.org>April 28th*The New Age of Molecular Testing and Targeted Therapies in Lung Cancer*

ACCC & AMP

<https://attendee.gotowebinar.com/register/2573310585943935235>May 2nd*Real-World Experience in Immunotherapy Delivery*ACCC
<https://attendee.gotowebinar.com/register/7533136073501009922>May 2nd*Update on Advanced Ovarian Cancer*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 3rd*Trends in Oncology and Treatment Planning: What You Need to Know (Part I of Life with Cancer: A Guide to Getting the Best Care)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 5th*Advances in the Treatment of Renal Cell Cancer*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 6th*Advances in Cancer Immunotherapy*

Society for Immunotherapy of Cancer

San Francisco

May 12th*Emerging Treatments for Metastatic Melanoma (Part II of Living with Advanced Skin Cancer)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 16th*Living with Chronic Myelogenous Leukemia (CML)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 17th*Understanding the Costs of Care and Your Health Care Coverage (Part II of Life with Cancer: A Guide to Getting the Best Care)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 18th*Progress in the Treatment of Multiple Myeloma*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 19th*The Role of Immunotherapy in the Treatment of Melanoma (Part III of Living with Advanced Skin Cancer)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 22nd*Preventing Chemotherapy Induced Nausea and Vomiting*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 23rd*Advances in the Treatment of Lung Cancer (Part I of Living with Lung Cancer)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsMay 24th*Cancer and the Workplace: Understanding Your Legal Protections (Part III of Life with Cancer: A Guide to Getting the Best Care)*

CancerCare Connect Education Workshop

www.cancercare.org/connect_workshopsJune 2nd-6th

2017 ASCO Annual Meeting

ASCO

Chicago

am.asco.orgJune 7th*Participating in Decisions about Your Care (Part IV of Life with Cancer: A Guide to Getting the Best Care)*

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for April 29th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTherapeutics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • EMD Serono • Exelixis
Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology •
Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology

We especially wish to thank and welcome *Agendia*, *bioTherapeutics*, *EMD Serono*, *Kite Pharmaceuticals*, and *Pfizer US Biosimilars* as new Corporate Members for 2017. Please visit

www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AstraZeneca informs ANCO that the *United States Food and Drug Administration* has approved Tagrisso for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

Merck's Test. Talk. Take Action website is an unbranded awareness campaign focused on increasing people's understanding of biomarkers and the role they play in the treatment of non-small cell lung cancer (NSCLC). Visit the website at www.TestTalkTakeAction.com.

Pfizer Oncology informs ANCO that the *United States Food and Drug Administration* has approved Ibrance in combination with any aromatase inhibitor for the initial treatment of postmenopausal women with HR+/HER2-metastatic breast cancer (MBC).

Tesaro informs ANCO that the *United States Food and Drug Administration* has approved Zejula as a maintenance therapy for women with recurrent ovarian cancer.

Clinical Trial News

The California Medical Association's (CMA) Foundation and its Network of Ethnic Physician Organizations (NEPO) have launched a campaign to increase minority participation in clinical studies. *Encouraging Diversity in Clinical Trials* hopes to increase clinical trial participation among California's multi-ethnic patient populations. Go to www.thecmafoundation.org/Programs/Clinical-Trials for more information.

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic

Squamous Cell Carcinoma of the Head and Neck (SCCHN). Principal Investigator: A. Dimitrios Colevas, MD; Contact: Stefania Ursu Chirita, (650) 723-1423, schirita@stanford.edu

- Phase II, Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD; LYMH0016; NCT02758717). Principal Investigator: Ranjana Advani, MD; Contact: Ann Moffatt, (650) 723-6498, amoffat@stanford.edu

- A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ECOG4512; NCT02201992). Principal Investigator: Heather Wakelee, MD; Contact: Marina Steffen, (650) 721-4077, steffenm@stanford.edu

- A Phase 1b study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epcadostat (INCB24360) in Patients with Recurrent Ovarian Cancer (GYNOVA0039; NCT02785250). Principal Investigator: Oliver Dorigo, MD; Contact: Dona Bahmani, (650) 724-3308, dbahmani@stanford.edu

- A Phase III Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (GOG3005; NCT02470585; NCT02134197). Principal Investigator: Oliver Dorigo, MD; Contact: Madelyn Gutierrez Gomez, (650) 723-0298, madelyng@stanford.edu

- POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer): A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy (NRGA221405; NCT02308085). Principal Investigator: Irene Wapnir, MD; Contact: Caitlin Plahn, (650) 723-3046, cplahn@stanford.edu

- An Open-Label Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY 1129980 in Subjects with Advanced Solid Tumors Known to Express C4.4a (VAR0146; NCT02134197). Principal Investigator: Shivaani Kummar, MD; Contact: Ferial Buchholz, (650) 721-4090, ferielbu@stanford.edu

- Intratumoral Injection of SD-101, an Immunostimulatory CpG, in combination with Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma

(LYMNL0135; NCT02927964]. Principal Investigator: Ronald Levy, MD; Contact: Destiny Phillips, (650) 498-1313, destiny@stanford.edu or Hollis Moore, (650) 725-8589, hollis.moore@stanford.edu

Further information is available at cancer.stanford.edu/trials/.

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors (CC#149511). Contact: Jenna Zhang, (415) 514-8867, jenna.zhang@ucsf.edu
- A Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients with Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy is Available (CC#159512). Contact: Emily Boyd, (415) 514-6638, emily.boyd2@ucsf.edu.
- An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors (CC#16955). Contact: Emily Boyd, (415) 514-6638; emily.boyd2@ucsf.edu
- A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities (CC#17455). Contact: Maddy Griffith, (415) 476-7974; madeline.griffith@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ASCO's *Clinical Affairs Department* is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco-s-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

ASCO has updated its cancer clinical practice guideline for the treatment of potentially curable pancreatic cancer, focusing specifically on the adjuvant treatment of R0 or R1 resected disease. The updated guideline appeared in the *Journal of Clinical Oncology* on April 11th.

ASCO and *Innovative Oncology Business Solutions* (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA and will be available across the country starting on January 1st, 2017. ASCO is now recruiting practices for the fee-based 2017 ASCO COME HOME program. For more information, please contact Elaine Towle (elaine.towle@asco.org). Learn more about ASCO's physician payment reform efforts at www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

On March 14th, the Spring Round for ASCO's QOPI opened for reporting. The Spring Round will close on May 9th. Learn more at www.asco.org/advocacy-policy/asco-in-action/qopi-spring-round-reporting-opens-march-14-register-now.

In 2017, practices will also be able to use the QOPI platform to meet the MIPS reporting requirement of one measure through manual reporting. While one measure is the minimum requirement to avoid the 2019 penalty, ASCO encourages all practices to report on at least four measure to become fully acquainted with the system and ensure that the CMS requirements are met.

The March/April issue of ACCC's *Oncology Issues* includes articles entitled *Spiritual Care of Cancer*

Patients, Implementing Telephone Triage Guidelines into Nursing Workflow, Advancing Immunotherapy in the Community Setting. Visit www.accc-cancer.org/oncology_issues to read this issue.

ACCC's 2017 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org. **ASH also has a webpage** (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs. Finally, ***assistPoint*** is your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

ASH is now accepting nominations for members to participate in its 7th annual Advocacy Leadership Institute taking place September 27-28th in Washington, D.C. This two-day workshop is an opportunity for ASH members who wish to learn about legislation and health policy affecting hematology research and practice. Nominations are being accepted through June 16th. Learn more at www.hematology.org/Advocacy/ALI.aspx.

NCCN has published and/or updated their Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Guidelines for Patients, and/or Imaging Appropriate Use Criteria for adult cancer pain (V1.2017); anal cancer; antiemesis (V2.2017); B-cell lymphomas (V3.2017); breast cancer (V2.2017); cancer-related fatigue (V2.2017); diffuse large B-cell lymphoma (V1.2017); chronic lymphocytic leukemia/small

lymphocytic lymphoma; colon cancer; distress (V1.2017); esophageal and esophagogastric cancer (V1.2017); follicular lymphoma (V1.2017); gastric cancer (V1.2017); hairy cell leukemia; hepatobiliary cancer; metastatic breast cancer (stage IV; V1.2017); neuroendocrine tumors (V2.2017); non-small cell lung cancer (V5.2017); ovarian cancer (V1.2017); pancreatic carcinoma (V1.2017); primary cutaneous B-cell lymphomas; rectal cancer; smoking cessation (V1.2017); soft tissue sarcoma; survivorship (V1.2017); systemic light chain amyloidosis; testicular cancer; T-cell lymphomas; thyroid carcinoma (V1.2017); uterine neoplasms (endometrial carcinoma; V1.2017); Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Go to www.nccn.org for more information. NCCN is pleased to offer pocket-sized versions of the *NCCN Clinical Practice Guidelines in Oncology* for a number of their guidelines at www.nccn.org/redirects/nicelines.asp?Type=general.

Oplinc is a national organization that was founded with the purpose of developing a collaborative environment within the oncology community. The ***Oplinc Best Practices Review Newsletter***, sponsored by *Lilly Oncology* and written by Risë Cleland, provides an in-depth look at the issues and challenges facing oncology practices. Download the latest edition (focusing on health care fraud and abuse control programs) at www.oplinc.com/newsletter/BestPracticesReviewApril2017.html.

Individual Membership Dues for 2017

Third notices of membership renewal for 2015 were mailed in early April. If you have not yet done so, then please return your 2017 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.